

Luisella Bocchio-Chiavetto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7085904/publications.pdf>

Version: 2024-02-01

68
papers

4,379
citations

109137

35
h-index

106150

65
g-index

68
all docs

68
docs citations

68
times ranked

7591
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 763-773.	1.3	363
2	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
3	Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. <i>Molecular Psychiatry</i> , 2002, 7, 136-137.	4.1	223
4	Blood microRNA changes in depressed patients during antidepressant treatment. <i>European Neuropsychopharmacology</i> , 2013, 23, 602-611.	0.3	197
5	Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. <i>Schizophrenia Research</i> , 2002, 54, 281-291.	1.1	155
6	Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. <i>European Neuropsychopharmacology</i> , 2006, 16, 620-624.	0.3	149
7	Peripheral whole blood microRNA alterations in major depression and bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 200, 250-258.	2.0	138
8	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. <i>Journal of Affective Disorders</i> , 2006, 91, 83-86.	2.0	137
9	Serum Brain-Derived Neurotrophic Factor Levels in Different Neurological Diseases. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	137
10	Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. <i>European Neuropsychopharmacology</i> , 2000, 10, 119-124.	0.3	127
11	Gene-Environment Interaction in Major Depression: Focus on Experience-Dependent Biological Systems. <i>Frontiers in Psychiatry</i> , 2015, 6, 68.	1.3	113
12	Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 40.	1.8	110
13	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109
14	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 75.	1.8	100
15	Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1 β mRNA Levels Accurately Predict Treatment Response in Depressed Patients. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw045.	1.0	100
16	Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease. <i>Annals of Neurology</i> , 2014, 76, 813-825.	2.8	91
17	Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 103.	1.0	82
18	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. <i>Biological Psychiatry</i> , 2002, 51, 480-484.	0.7	81

#	ARTICLE	IF	CITATIONS
19	Markers of Alzheimer's disease in a population attending a memory clinic. <i>Alzheimer's and Dementia</i> , 2009, 5, 307-317.	0.4	80
20	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. <i>Neuroscience Letters</i> , 2008, 437, 130-134.	1.0	79
21	Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: A case-control study. <i>Journal of Affective Disorders</i> , 2010, 122, 174-178.	2.0	76
22	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 82, 102-109.	1.5	76
23	Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1322-1325.	2.5	73
24	Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. <i>PLoS ONE</i> , 2015, 10, e0116686.	1.1	65
25	VEGF serum levels in depressed patients during SSRI antidepressant treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 146-149.	2.5	61
26	BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 323-329.	1.8	54
27	Association between IL-1 β -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. <i>Journal of Psychiatric Research</i> , 2003, 37, 457-462.	1.5	52
28	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013, 9, 677-686.	0.4	51
29	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. <i>Journal of Neurology</i> , 2013, 260, 640-650.	1.8	50
30	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 356, 119-122.	1.0	49
31	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. <i>Trials</i> , 2012, 13, 73.	0.7	47
32	-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study. <i>Brain, Behavior, and Immunity</i> , 2007, 21, 450-457.	2.0	44
33	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. <i>Journal of Neurology</i> , 2010, 257, 2004-2014.	1.8	44
34	Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16. <i>Psychiatry Research</i> , 2001, 104, 1-9.	1.7	40
35	Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder (ADHD). <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 173-177.	2.8	40
36	Abnormal Levels of cAMP-dependent Protein Kinase Regulatory Subunits in Platelets from Schizophrenic Patients. <i>Neuropsychopharmacology</i> , 2000, 23, 216-219.	2.8	36

#	ARTICLE	IF	CITATIONS
37	Alterations of Brain-Derived Neurotrophic Factor Serum Levels in Patients with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, no-no.	1.4	36
38	Distinct cerebrospinal fluid amyloid β peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. <i>Electrophoresis</i> , 2012, 33, 3738-3744.	1.3	34
39	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 461-466.	2.2	34
40	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. <i>BioTechniques</i> , 2014, 57, 111-114.	0.8	34
41	Glucose metabolism alterations in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2015, 184, 293-298.	2.0	34
42	Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. <i>European Journal of Human Genetics</i> , 2006, 14, 443-449.	1.4	33
43	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. <i>Alzheimer's and Dementia</i> , 2012, 8, 520-527.	0.4	32
44	Immune and metabolic alterations in first episode psychosis (FEP) patients. <i>Brain, Behavior, and Immunity</i> , 2018, 70, 315-324.	2.0	31
45	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	1.5	30
46	Association Study of ϵ 1727 A/T, ϵ 50 C/T and (CAA) _n Repeat GSK-3 β Gene Polymorphisms with Schizophrenia. <i>Neuropsychobiology</i> , 2004, 50, 16-20.	0.9	29
47	Allelic Variation in the Human Prodynorphin Gene Promoter and Schizophrenia. <i>Neuropsychobiology</i> , 2002, 46, 17-21.	0.9	27
48	Effects of Intranasal Oxytocin on Long-Term Memory in Healthy Humans: A Systematic Review. <i>Drug Development Research</i> , 2016, 77, 479-488.	1.4	25
49	BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. <i>Journal of ECT</i> , 2019, 35, 189-194.	0.3	19
50	miR-146a Plasma Levels Are Not Altered in Alzheimer's Disease but Correlate With Age and Illness Severity. <i>Frontiers in Aging Neuroscience</i> , 2020, 11, 366.	1.7	17
51	Oxidation of propenoidic phenols catalysed by N,N ϵ -ethylenebis(salicylideneiminato)cobalt(II) [Cosalen]: reactivity and spectroscopic studies. <i>Journal of Molecular Catalysis A</i> , 1996, 112, 347-351.	4.8	16
52	BDNF Val66Met polymorphism and protein levels in Amniotic Fluid. <i>BMC Neuroscience</i> , 2010, 11, 16.	0.8	16
53	Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients. <i>H\ddot{a}gskola Utbildning</i> , 2021, 12, 1987655.	1.4	16
54	Childhood trauma and glucose metabolism in patients with first-episode psychosis. <i>Psychoneuroendocrinology</i> , 2020, 113, 104536.	1.3	15

#	ARTICLE	IF	CITATIONS
55	Correlations between immune and metabolic serum markers and schizophrenia/bipolar disorder polygenic risk score in first-episode psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 507-511.	0.9	15
56	Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response. <i>Drug Development Research</i> , 2020, 81, 593-599.	1.4	14
57	Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 79, 712-715.	0.9	12
58	Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 610-618.	1.3	12
59	Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes. <i>Molecular and Cellular Neurosciences</i> , 2017, 85, 220-225.	1.0	11
60	Oxidation of isosafrole by sodium hypochlorite catalysed by manganese porphyrins: Unusual competition between epoxidation and O-dealkylation. <i>Tetrahedron Letters</i> , 1996, 37, 1091-1094.	0.7	9
61	Lack of association between MnSOD gene polymorphism and sporadic Alzheimer's Disease. <i>Aging Clinical and Experimental Research</i> , 2005, 17, 445-448.	1.4	9
62	Season of birth and inflammatory response system in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 879-880.	2.5	8
63	Effect of the XbaI polymorphism of estrogen receptor alpha on postmenopausal gray matter. <i>Neuroscience Letters</i> , 2008, 434, 304-309.	1.0	8
64	Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study. <i>Neuropsychobiology</i> , 2016, 74, 15-21.	0.9	8
65	Nanomedicine in Psychiatry: New Therapeutic Opportunities from Research on Small RNAs. <i>Drug Development Research</i> , 2016, 77, 453-457.	1.4	4
66	No occurrence of the glutamate transporter EAAT2 A206G polymorphism in schizophrenic subjects. <i>Molecular Psychiatry</i> , 2002, 7, 671-672.	4.1	3
67	Effetti biomolecolari del maltrattamento infantile: il ruolo dell'epigenetica e dell'infiammazione. <i>Maltrattamento E Abuso All'Infanzia</i> , 2015, , 35-54.	0.2	3
68	Aspetti biologici e neuropsicologici del maltrattamento e abuso infantili. <i>Maltrattamento E Abuso All'Infanzia</i> , 2015, , 7-10.	0.2	2